tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Compass Therapeutics initiated with a Buy at Craig-Hallum
PremiumThe FlyCompass Therapeutics initiated with a Buy at Craig-Hallum
19d ago
Compass Therapeutics price target raised to $13 from $10 at Canaccord
Premium
The Fly
Compass Therapeutics price target raised to $13 from $10 at Canaccord
28d ago
Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential
Premium
Ratings
Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential
2M ago
Compass Therapeutics initiated with an Outperform at William Blair
PremiumThe FlyCompass Therapeutics initiated with an Outperform at William Blair
2M ago
Compass Therapeutics: Emerging Bispecific Portfolio Positions Tovecimig to Redefine Second-Line Biliary Tract Cancer Standard of Care
Premium
Ratings
Compass Therapeutics: Emerging Bispecific Portfolio Positions Tovecimig to Redefine Second-Line Biliary Tract Cancer Standard of Care
2M ago
High-Conviction Buy on Compass Therapeutics: Near-Term Tovecimig Registration Data and Differentiated PD-1 x PD-L1 Bispecific Drive Favorable Risk-Reward
Premium
Ratings
High-Conviction Buy on Compass Therapeutics: Near-Term Tovecimig Registration Data and Differentiated PD-1 x PD-L1 Bispecific Drive Favorable Risk-Reward
2M ago
Compass Therapeutics initiated with a Buy at Canaccord
PremiumThe FlyCompass Therapeutics initiated with a Buy at Canaccord
3M ago
Compass Therapeutics initiated with an Outperform at Citizens JMP
Premium
The Fly
Compass Therapeutics initiated with an Outperform at Citizens JMP
3M ago
Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
Premium
Ratings
Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100